2026 National Health Care Fraud Takedown Highlights Shift Toward AI-Assisted Investigative Techniques

The Department of Justice (DOJ) announced last month that 455 defendants were charged in the 2026 National Health Care Fraud Takedown, including 90 doctors and other licensed medical professionals, in connection with more than $6.5 billion in alleged false claims. The government seized over $182 million in cash, luxury vehicles, jewelry, and other assets in the process.

Two themes stand out for health care companies. First, Medicaid enforcement has expanded dramatically, with more states participating than ever before. Second, DOJ is increasingly uncovering fraud using data analytics and artificial intelligence (AI), often before a dollar goes out the door.

These annual takedowns are not new. Since the Health Care Strike Force began in March 2007, it has charged more than 6,200 defendants that collectively billed federal programs and commercial insurers more than $45 billion. What has changed are the methods, which may expand the scale and reach of DOJ’s enforcement efforts and increase the speed with which it investigates and prosecutes health care fraud.

The headline numbers

DOJ reports that the 2026 takedown spanned 56 federal districts and 45 states and territories. Beyond the criminal charges, the Centers for Medicare & Medicaid Services (CMS) suspended 1,079 providers and revoked billing privileges for 1,403 more. The Office of the Inspector General for the Department of Health and Human Services (HHS-OIG) brought 25 cases under the Civil Monetary Penalties Law seeking more than $10 billion, secured 48 civil monetary penalty settlements totaling over $73 million, and imposed over 1,400 provider exclusions. The enforcement effort was led by the National Fraud Enforcement Division of DOJ, a newly created unit charged with overseeing multidistrict and multiagency fraud investigations as part of the 2026 push by the White House to prosecute those targeting federal government programs.

State participation and the expansion of Medicaid enforcement

The enforcement announcement featured 50 State Medicaid Fraud Control Units, the most in DOJ history. Cases were prosecuted with the help of 45 state Attorneys General, which reflects an increased level of cooperation between the federal and state governments. In the Eastern District of New York, for example, eight defendants were charged in a $38 million scheme for billing New York Medicaid for medically unnecessary adult daycare services procured by kickbacks. As another example, in the Eastern District of Virginia, the co-owner of a mental health company was charged in a $49 million Medicaid scheme that targeted homeless individuals with hotel-stay bribes in exchange for their Medicaid numbers. Meanwhile, in the District of Arizona, a defendant was charged with submitting $44 million in fraudulent behavioral service claims, primarily targeting Native Americans struggling with substance abuse. Companies that receive Medicaid reimbursement in any state should assume that they are within reach of coordinated federal and state enforcement efforts.

Wound care abuse remains squarely in DOJ crosshairs

DOJ charged 11 defendants across six districts, including a company executive and eight medical professionals, in connection with billions of dollars in fraudulent claims for wound allografts. Wound allografts are grafts made from donated human tissue used to cover and promote the healing of chronic wounds like diabetic ulcers and pressure sores. Historically, Medicare and other insurers have reimbursed practitioners for wound allografts at very expensive rates. But more recently, Medicare has dramatically reduced its reimbursement of allografts as their overuse has come to light.

On the heels of prosecutions of multiple individuals over the past year for schemes involving allografts, DOJ last month charged the Vice President of Sales for a major allograft company in Arizona for a nationwide illegal kickback and health care fraud scheme. DOJ alleges that the executive caused over $4 billion in Medicare billing for the company’s allografts, resulting in over $2 billion in payments. DOJ alleges the spike was driven by kickbacks rather than medical necessity, noting the company did not manufacture allografts but relabeled them for sale at a 2,000% markup. That resulted in charging up to $1,450 per square centimeter for the allografts. The executive allegedly personally obtained over $24 million, which he spent on multimillion-dollar homes, luxury vehicles, including a $135,000 Maserati, and luxury watches.

The wound care cases did not stop there. In the Southern District of Texas, a nurse practitioner was charged in a $906 million scheme in which she applied medically unnecessary allografts and billed Medicare more than $1 million per patient on average. The government seized over $30 million in bank accounts, a $594,000 Ferrari 296 GTS, seven other high-end vehicles, and an $865,000 custom Bulgari necklace, among other assets, and identified proceeds allegedly used to fund a $4.6 million beach resort in the Philippines. In the Middle District of Florida, three defendants were charged in a $118 million allograft scheme in which a nurse practitioner allegedly funded a luxury box at an NFL stadium and bought over $400,000 in fine art.

Notably, DOJ reports that it was its Health Care Fraud Unit’s Data Analytics Team that detected the spike in allograft payments that led to these prosecutions. For example, in the Southern District of Florida, a data-driven “follow and seize the money” effort recovered over $27 million tied to 12 clinics billing for allografts never provided.

Data analytics and AI are now the tip of the spear for federal law enforcement

DOJ repeatedly credited its expanding use of analytics and AI for driving these cases. The most important shift is timing. CMS and the Health Care Fraud Unit are running analytics against claims data in close to real time, and DOJ’s stated goal is to stop payments “before a single dollar leaves the building.” In one Medicaid case, prosecutors opened an investigation within five days of identifying suspicious data and financial transactions, and the defendant was arrested less than seven months later.

Companies should treat their own billing data as an early-warning system. Anomalous volume, sudden spikes tied to a single product or code, outlier utilization by particular providers, and payment patterns that diverge from clinical norms are signals that DOJ and HHS-OIG are monitoring.

Companies should invest in data analytics that mirror the government’s approach

Companies should try to identify outliers in their data as quickly as possible to ensure they learn about and remediate potential issues before DOJ does. This includes confirming medical necessity documentation; scrutinizing all payment arrangements to marketing and sales staff, especially ones that are tied to volume; paying close attention to Medicaid compliance across every state in which the company operates; and ensuring that compliance has direct access to top executives who emphasize its importance to the company through compliance bonuses and discipline for infractions.

Please contact a member of Lowenstein Sandler’s White Collar Defense group with questions about how these developments may affect your organization.